We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.8888 | 3.47% | 26.5088 | 26.97 | 26.02 | 26.3295 | 35,586,623 | 16:36:01 |
From May 2022 to May 2024
By Denny Jacob
Pfizer Inc. and BioNTech SE on Wednesday said regulators recommended marketing authorization for a Covid-19 vaccine as a three-dose series for children ages 6 months to 4 years old.
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for a 3-ug dose of Comirnaty. The European Commission will review the committee's recommendation and is expected to make a final decision soon, the companies said.
The U.S. Food and Drug Administration granted emergency use authorization of the original Pfizer-BioNTech Covid-19 vaccine as a three 3-ug dose series in this age group in June.
Pfizer and BioNTech said they also are in discussions with health authorities regarding a regulatory pathway for potential authorization of a different Covid-19 vaccine for use in children under 5 years of age.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 19, 2022 12:20 ET (16:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
